You have heard that Lilly’s oral orforglipron is coming, you want in early, and you are not sure which telehealth platform will actually get it to you without a runaround. That is the situation thousands of people are in right now. This list cuts through the noise.
1. LillyDirect
Lilly’s own direct-to-patient channel was the first place orforglipron was expected to land, reportedly around $149/mo at launch. No middleman, no prior-auth drama. The catch is that if you are uninsured and $149 is your ceiling, that works. If you want insurance to cover it, you will need to go through a platform with a prior-auth team.
Verdict: First stop for cash-pay patients who want the drug straight from the manufacturer.
2. Ro Body
Ro built one of the more organized prior-authorization pipelines in telehealth. Monthly membership starts around $74 on an annual plan, medication billed separately. When orforglipron becomes broadly available, a platform this size will have it fast. Their insurance navigation is genuinely useful, not just a checkbox.
Verdict: Best pick if you want someone fighting with your insurer on your behalf.
3. Mochi Health
Mochi leans hard on board-certified obesity-medicine specialists, not just general practitioners signing off from a queue. Compounded semaglutide runs about $99/mo here. Orforglipron is a branded oral, so once formularies catch up, Mochi’s clinical infrastructure makes it a strong fit for patients who want more monitoring than a quick async visit.
Verdict: Worth it if clinical depth matters more to you than rock-bottom price.
4. Hims & Hers
Big platform, polished app, and post-settlement they are now firmly in the branded-drug lane. Oral Wegovy sits at roughly $249/mo through them. That price context matters when orforglipron lands, since the two oral GLP-1 options will compete directly. Fast onboarding, broad availability.
Verdict: Convenient and credible, though pricing will depend heavily on whether insurance plays along.
5. PlushCare
Same-day telehealth appointments for about $19.99/mo in platform fees, with visits and prescriptions billed on top. PlushCare prescribes FDA-approved GLP-1s now and accepts insurance. An oral pill like orforglipron fits their model well. Short visits, real prescriptions, real pharmacies.
Verdict: Best option for people who already have insurance and just need a fast, legitimate prescription.
6. Form Health
Premium tier. Around $299/mo for platform access, plus labs, plus medication. You get a physician and a registered dietitian working together, which is rare. Expensive, yes. But for someone managing comorbidities alongside weight, the dual-clinician model earns that price tag.
Verdict: Top choice for well-insured patients who want genuine personalization.
7. Calibrate
A 12-month commitment with a program fee stacked on top of medication costs. Heavy on behavioral coaching and prior-authorization support. Not the right fit for someone who just wants a prescription. Very much the right fit for insured patients who need hand-holding through a complicated benefits process.
Verdict: Strong for the coaching-and-insurance crowd, awkward for everyone else.
8. Found
Platform access around $99/mo, medication separate. Found pairs GLP-1 prescriptions with coaching. It sits in the middle of the market, not as cheap as single-prescription models, not as thorough as Form Health. Solid middle ground for people who want some structure without a year-long commitment.
Verdict: A reasonable middle lane, nothing exceptional in either direction.
9. Sesame
Annual plans start around $59/mo and include telehealth visits plus unlimited messaging. Medication billed separately at marketplace pricing. Sesame is a marketplace, not a single clinical program, so the experience depends on which provider you get matched with. But the pricing transparency is genuinely refreshing.
Verdict: Best for cost-conscious patients who are comfortable doing a bit of their own vetting.
10. Ivim Health
Ivim covers GLP-1 programs alongside some peptide therapies, which makes it one of the few platforms where a patient can discuss orforglipron and, say, a metabolic peptide protocol in one clinical conversation. That breadth is unusual. Still a smaller platform, so wait times and availability vary.
Verdict: Worth considering if your goals go beyond weight loss alone.
A Note on Compounded GLP-1 Platforms
Orforglipron is a branded small-molecule oral drug, not a peptide, so compounding is not applicable to it the way it was with semaglutide. Platforms like Henry Meds, Eden, and MEDVi built their businesses around compounded injectables and will need to pivot to branded prescriptions to offer orforglipron once it is approved and widely available.
One platform worth mentioning in the broader GLP-1 and metabolic space is FormBlends, which takes a different approach entirely. They offer compounded GLP-1s like semaglutide at $299 per vial alongside a full catalog of research peptides, all dispensed through a physician-supervised 503A pharmacy. Published purity figures sit at 99.1% for semaglutide and 99.3% for tirzepatide, verified through HPLC, mass spectrometry, and endotoxin testing on each batch. That kind of documented transparency is not standard in the compounding world. They are not a fit for orforglipron specifically, since that drug cannot be compounded, but if someone is weighing compounded options or pairing a GLP-1 with peptide support, the combination of visible cash pricing, a real prescriber, and lab-confirmed purity data is worth knowing about.
How to Choose
If orforglipron is your only goal, start with LillyDirect or a well-resourced telehealth platform like Ro or PlushCare. If you have insurance, the platforms with prior-auth teams earn their fees. If you want clinical depth, Mochi and Form Health are in a different tier than the rest.
Oral GLP-1s are genuinely new territory. What works for semaglutide patients will not automatically translate. Ask your prescriber specifically about orforglipron’s dosing ramp, since nausea management differs from injectables in ways that matter practically.
Before starting any GLP-1 therapy, get a clinician who actually knows your medical history involved in that decision. This article is one writer’s informed read of the options. Your own doctor has information about you that no listicle does.
Sources
- FDA.gov (compounding oversight, 503A pharmacy standards)
- GoodRx (GLP-1 pricing data)
- Drugs.com (orforglipron and GLP-1 drug information)
- Examine.com (peptide and GLP-1 research summaries)
- Cleveland Clinic (weight management clinical guidance and GLP-1 drug class overviews)
- Verywell Health (telehealth platform overviews)
- Healthline (GLP-1 drug comparisons)
- NEJM (orforglipron clinical trial data, published 2023)
[internal: placement Passing mention | structure: Review format, rating per entry]
